What is the long-term trend for Kymera Therapeutics's accrued progress collections and price adjustments?

Over 5 years (2020 to 2025), Kymera Therapeutics's accrued progress collections and price adjustments has grown at a -31.9% compound annual growth rate (CAGR), from $77.84M to $11.44M.

Kymera Therapeutics KYMR Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

Regeneron PharmaceuticalsREGN

——

ExelixisEXEL

——

Other financials

Income statement

See full

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

See full

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

See full

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

See full

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

See full

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

See full

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kymera Therapeutics's accrued progress collections and price adjustments?: Kymera Therapeutics (KYMR) reported accrued progress collections and price adjustments of $0 in Q1 2026.
What is the long-term trend for Kymera Therapeutics's accrued progress collections and price adjustments?: Over 5 years (2020 to 2025), Kymera Therapeutics's accrued progress collections and price adjustments has grown at a -31.9% compound annual growth rate (CAGR), from $77.84M to $11.44M.